Open Access
| Issue |
BIO Web Conf.
Volume 174, 2025
2025 7th International Conference on Biotechnology and Biomedicine (ICBB 2025)
|
|
|---|---|---|
| Article Number | 02022 | |
| Number of page(s) | 6 | |
| Section | Innovations in Therapeutics and Disease Mechanisms | |
| DOI | https://doi.org/10.1051/bioconf/202517402022 | |
| Published online | 12 May 2025 | |
- Khoury, J. D., Solary, E., Abla, O., Akkari, Y., Alaggio, R., Apperley, J. F., ... & Hochhaus, A. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. leukemia, 2022, 36.7: 1703-1719. [CrossRef] [PubMed] [Google Scholar]
- https://www.cancer.org/cancer/acute-myeloid-leuke mia/about/key-statistics.html.(accessed 2025-2-19) [Google Scholar]
- Daver, N.; Schlenk, R. F.; Russell, N. H.; Levis, M. J. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia 2019, 33 (2), 299-312. [CrossRef] [PubMed] [Google Scholar]
- M. Békés, D.R. Langley, C.M. Crews, PROTAC targeted protein degraders: the past is prologue, Nat. Rev. Drug Discov. 21 (2022) 181–200 [CrossRef] [PubMed] [Google Scholar]
- Burslem GM, Song J, Chen X, et al. Enhancing antiproliferative activity and selectivity of a FLT3 inhibitor by proteolysis targeting chimera conversion [J]. J Am Chem Soc, 2018, 140:16428-16432. [CrossRef] [PubMed] [Google Scholar]
- Huang HT, Dobrovolsky D, Paulk J, et al. A chemoproteomic approach to query the degradable kinome using a multi-kinase degrader [J]. Cell Chem Biol, 2018, 25: 88-99.e6. [CrossRef] [Google Scholar]
- Cao S, Ma L, Liu Y, et al. Proteolysis-targeting chimera (PROTAC) modification of dovitinib enhances the antiproliferative effect against FLT3-ITD-positive acute myeloid leukemia cells [J]. J Med Chem, 2021, 64: 16497-16511 [CrossRef] [PubMed] [Google Scholar]
- Chen Y, Yuan X, Tang M, et al. Degrading FLT3-ITD protein by proteolysis targeting chimera (PROTAC) [J]. Bioorg Chem, 2022, 119: 105508. [CrossRef] [Google Scholar]
- Wang J, Rong Q, Ye L, Fang B, Zhao Y, Sun Y, Zhou H, Wang D, He J, Cui Z, Zhang Q, Kang D, Hu L. Discovery of a Novel Orally Bioavailable FLT3-PROTAC Degrader for Efficient Treatment of Acute Myeloid Leukemia and Overcoming Resistance of FLT3 Inhibitors. J Med Chem. 2024 May 9; 67(9): 7197-7223. doi: 10.1021/acs.jmedchem.4c00051. Epub 2024 Apr 24. PMID: 38655686. [CrossRef] [PubMed] [Google Scholar]
- Liu W, Bai Y, Zhou L, et al. Discovery of LWY713 as a potent and selective FLT3 PROTAC degrader with in vivo activity against acute myeloid leukemia. Eur J Med Chem. 2024;264:115974. doi:10.1016/j.ejmech.2023.115974 [CrossRef] [Google Scholar]
- Yokoo H, Tsuji G, Inoue T, Naito M, Demizu Y, Ohoka N. Expansion of targeted degradation by Gilteritinib-Warheaded PROTACs to ALK fusion proteins. Bioorg Chem. 2024;145:107204. doi:10.1016/j.bioorg.2024.107204 [CrossRef] [Google Scholar]
- Wang Z, Lu X, Liu C, et al. Discovery of FLT3-targeting PROTACs with potent antiproliferative activity against acute myeloid leukemia cells harboring FLT3 mutations. Eur J Med Chem. 2024;268:116237. doi:10.1016/j.ejmech.2024.116237 [CrossRef] [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.